专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2018087296A1 IMPROVED EBV VACCINE 审中-公开
标题翻译：改进的EBV疫苗
公开(公告)号：WO2018087296A1
公开(公告)日：2018-05-17
申请号：PCT/EP2017/078898
申请日：2017-11-10
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM
发明人： DELECLUSE, Henri-Jacques , SHUMILOV, Anatoliy , TSAI, Ming-Han
IPC分类号： A61K39/12
摘要： The present invention relates to a composition comprising Epstein-Barr Virus (EBV) particles for use in vaccination of a subject, wherein said EBV particles comprise a significantly reduced chromosome instability-inducing EBV polypeptide activity. The present invention also relates to a composition comprising EBV particles for use in vaccination of a subject, wherein said vaccination comprises avoiding contacting the cytosol and/or nucleus of cells of said subject with a chromosome instability-inducing EBV polypeptide activity. Moreover, the present invention relates to polynucleotides, host cells, methods, and uses related to the aforesaid compositions.
摘要翻译：本发明涉及用于接种受试者的包含EB病毒（EBV）颗粒的组合物，其中所述EBV颗粒包含显着降低的染色体不稳定性诱导的EBV多肽活性。本发明还涉及用于接种受试者的包含EBV颗粒的组合物，其中所述接种包括避免使所述受试者的细胞的细胞溶质和/或细胞核与染色体不稳定性诱导的EBV多肽活性接触。此外，本发明涉及涉及上述组合物的多核苷酸，宿主细胞，方法和用途。

2. 发明申请

WO2013139789A1 B-CELL RECEPTOR COMPLEX BINDING PROTEINS CONTAINING T-CELL EPITOPES 审中-公开
标题翻译： B细胞受体复合物包含T细胞外膜蛋白的蛋白质
公开(公告)号：WO2013139789A1
公开(公告)日：2013-09-26
申请号：PCT/EP2013/055690
申请日：2013-03-19
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM
发明人： DELECLUSE, Henri-Jacques , FEEDERLE, Regina , BARTLETT, Emmalene
IPC分类号： A61K39/00 , C07K14/05 , C07K16/28 , C07K19/00
CPC分类号： C07K14/005 , A61K39/12 , A61K39/245 , A61K2039/55516 , A61K2039/572 , A61K2039/585 , A61K2039/6056 , C07K16/2803 , C07K16/2896 , C07K2317/569 , C07K2319/33 , C12N7/00 , C12N2710/16222 , C12N2710/16234
摘要： The present invention relates to a polypeptide comprising a) a binding peptide binding to at least one protein selected from the group consisting of CD22, CD19, CD20, and CD21, and b) an immunogenic peptide comprising at least one T-cell epitope for use in vaccination of a subject against B-cell hyperproliferation or for use in the modulation of the immune response in a subject.. The present invention further relates to a polynucleotide and a vector encoding said polypeptide and a host cell comprising the same. It also relates to a method for the stimulation of antigen-specific T-cells, comprising a) contacting antigen presenting cells (APC) with a polypeptide, the polynucleotide, or the vector of the invention, b) contacting said APC with T-cells, and c) thereby stimulating antigen-specific T-cells specific for said at least one T-cell epitope; to a method for immunizing a subject against B- cell hyperproliferation, to a method for immunizing a subject against an infectious agent, and to a method for inducing tolerance in a subject.
摘要翻译：本发明涉及包含a）与至少一种选自CD22，CD19，CD20和CD21的蛋白结合的结合肽，和b）包含至少一个T细胞表位的免疫原性肽用于本发明还涉及编码所述多肽的多核苷酸和载体以及包含该多核苷酸的宿主细胞。它还涉及刺激抗原特异性T细胞的方法，其包括a）使抗原呈递细胞（APC）与本发明的多肽，多核苷酸或载体接触，b）使所述APC与T细胞接触和c）从而刺激对所述至少一种T细胞表位特异的抗原特异性T细胞; 涉及免疫受试者抗B-细胞过度增殖的方法，抗受感染剂免疫受试者的方法以及诱导受试者耐受的方法。

3. 发明申请

WO2013098364A1 SECOND GENERATION VIRUS-LIKE PARTICLES (VLP) FROM EPSTEIN-BARR VIRUSES FOR VACCINATION PURPOSES 审中-公开
标题翻译：来自用于疫苗用途的EPSTEIN-BARR病毒的第二代病毒样颗粒（VLP）
公开(公告)号：WO2013098364A1
公开(公告)日：2013-07-04
申请号：PCT/EP2012/077007
申请日：2012-12-28
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM
发明人： FEEDERLE, Regina , PAVLOVA, Sophia , DELECLUSE, Henri-Jacques
IPC分类号： A61K39/12 , C12N7/00 , C12N15/86
CPC分类号： A61K39/245 , A61K39/12 , A61K2039/525 , A61K2039/5258 , C07K14/005 , C07K14/05 , C07K16/081 , C12N7/00 , C12N15/86 , C12N2700/00 , C12N2710/00041 , C12N2710/10021 , C12N2710/16134 , C12N2710/16171 , C12N2710/16223 , C12N2710/16234 , C12N2710/16242 , C12N2710/16243 , C12N2710/16262 , C12N2710/16634 , C12N2710/16734 , C12N2710/20034 , C12N2800/204
摘要： The present invention relates to an Epstein-Barr virus-like particle (EB-VLP) substantially free of Epstein-Barr Virus (EBV) DNA. The present invention also relates to a polynucleotide comprising an EBV genome a) lacking at least one expressible gene selected from the group consisting of the BFLF1 gene, the BBRF gene, the BGRF1 gene, the BDRF1 gene, the BALF3 gene, the BFRF1A gene, and the BFRF1 gene, and b) producing the EB-VLP of the invention in a suitable host cell. The present invention further relates to a vector and a host cell comprising the polynucleotide of the invention as well to a method of manufacturing said EB-VLPs, a method of manufacturing a vaccine thereof, a vaccine and a composition comprising said EB-VLPs.
摘要翻译：本发明涉及基本上不含爱泼斯坦 - 巴尔病毒（EBV）DNA的爱泼斯坦 - 巴尔病毒样颗粒（EB-VLP）。本发明还涉及包含EBV基因组的多核苷酸a）缺少选自BFLF1基因，BBRF基因，BGRF1基因，BDRF1基因，BALF3基因，BFRF1A基因中的至少一种可表达基因，和BFRF1基因，以及b）在合适的宿主细胞中产生本发明的EB-VLP。本发明还涉及包含本发明的多核苷酸的载体和宿主细胞以及制备所述EB-VLP的方法，其疫苗的制备方法，疫苗和包含所述EB-VLP的组合物。

4. 发明申请

WO2021013932A1 POLYPEPTIDES FOR TREATMENT OF AML 审中-公开
公开(公告)号：WO2021013932A1
公开(公告)日：2021-01-28
申请号：PCT/EP2020/070809
申请日：2020-07-23
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM
发明人： DELECLUSE, Henri-Jacques , ILECKA, Marta , WASSMER, Guillaume
IPC分类号： C07K16/28 , A61K39/12 , C07K14/05 , G01N33/574
摘要： The present invention relates to a polypeptide comprising (i) a binding peptide binding to at least one surface marker of an acute myeloid leukemia (AML) cell, and (ii) an immunogenic peptide comprising at least one T-cell epitope; and to means and methods related thereto.

5. 发明申请

WO2020074708A1 EPSTEIN-BARR VIRUS-LIKE PARTICLES WITH BROADENED ANTIGENIC SPECTRUM 审中-公开
公开(公告)号：WO2020074708A1
公开(公告)日：2020-04-16
申请号：PCT/EP2019/077605
申请日：2019-10-11
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM
发明人： DELECLUSE, Henri-Jacques , VAN ZYL, Dwain
IPC分类号： A61K39/245 , A61K38/16
摘要： The present invention relates to a preparation comprising Epstein-Barr vius-like particles (EB-VLPs), said EB-VLPs being essentially free of Epstein Barr virus (EBV) DNA, wherein said EB-VLPs comprise a vaccination polypeptide comprising at least one peptide of an EBV tegument polypeptide and at least one immunogenic peptide; and to polynucleotides, host cells, and methods related thereto.

6. 发明申请

WO2009068615A1 EX VIVO METHOD FOR PRODUCING A PREPARATION CONTAINING CD4+ T CELLS SPECIFIC FOR EBV STRUCTURAL ANTIGENS 审中-公开
标题翻译：用于生产含有EBV结构抗原特异性CD4 + T细胞的制备物的生物方法
公开(公告)号：WO2009068615A1
公开(公告)日：2009-06-04
申请号：PCT/EP2008/066347
申请日：2008-11-27
申请人： HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) , DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) , ADHIKARY, Dinesh , BEHRENDS, Uta , MAUTNER, Josef , DELECLUSE, Henri-Jacques , FEEDERLE, Regine
发明人： ADHIKARY, Dinesh , BEHRENDS, Uta , MAUTNER, Josef , DELECLUSE, Henri-Jacques , FEEDERLE, Regine
IPC分类号： C12N5/06 , A61K35/12 , A61P37/04
CPC分类号： A61K39/245 , A61K39/12 , A61K2039/5158 , A61K2039/5258 , C12N5/0636 , C12N2502/11 , C12N2710/16234
摘要： The present invention discloses an ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens for use in the prophylaxis and treatment of patients with a reduced T cell activity in order to prevent or treat growth of EBV infected B cells.
摘要翻译：本发明公开了一种用于制备含有EBV结构抗原特异性CD4 + T细胞的制剂的离体方法，用于预防和治疗T细胞活性降低的患者，以预防或治疗EBV感染的B细胞的生长。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式